Mesenchymal stem/stromal cells (MSCs) are an important candidate for cell-based therapy since they can be easily isolated and expanded, secrete beneficial paracrine factors, and differentiate into multiple lineages. Since the endothelium at sites of injury and inflammation often express adhesion molecules belonging to the selectin family, methods to endow MSCs with selectin-ligands can enhance the efficacy of cell delivery and tissue engraftment. Here, we describe a construct 19Fc[ were captured/tethered onto stimulated endothelial cell monolayers at wall shear stresses up to 4 dyn/ cm 2 . Once captured, the cells rolled robustly up to the highest shear stress tested, 10 dyn/cm 2 . Unlike previous work where MSCs could only be captured onto selectin-bearing substrates at low or no-flow conditions, the current work presents a 'glycan engineering' strategy to enable leukocyte-like capture and rolling.
Introduction
Mesenchymal stem/stromal cell (MSC) therapy has shown great promise in the treatment of many autoimmune disorders and degenerative diseases such as graft-versus-host disease, systemic lupus erythematosus, multiple sclerosis, type 1 diabetes, myocardial infarction, liver cirrhosis and inflammatory bowel disease [1] . For such therapies, MSCs can be scaled-up to produce billions of cells from a single bone marrow aspirate or other connective tissue sources [2] . Once delivered to the target organ, the MSCs repair tissue by acting as a source of paracrine factors that promote cell survival and growth, regulate vascular permeability and promote immune-tolerance [1, 3] . A portion of these multipotent cells may also differentiate and integrate into various host tissue types including bone, adipose, cardiac, cartilage and muscle [2, 4] .
The effective use of MSC therapy requires the targeting of cells to the proximity of the tissue repair site with high efficiency. The direct local injection of MSCs into the tissue and the systemic infusion of these cells in blood vessels proximal to the therapeutic site represent two potential delivery routes. While both strategies are viable, systemic infusion has the advantage of being minimally invasive, and it circumvents problems associated with calcification and tissue damage [5, 6] . It can also be applied to target a broad region of the injured tissue that is perfused by blood rather than a local site that may or may not be oxygenated. A shortcoming of this approach, however, is that the efficiency of unmodified MSC captured from flowing blood onto the vascular endothelium is low since selectinligands like P-selectin glycoprotein ligand-1 (PSGL-1) are not expressed on these cells. The expression levels of other cell adhesion molecules like VLA-4 and the chemokine receptor CXCR4 on MSCs are also low (<10%) compared to primary leukocytes [7, 8] , and can be heterogeneous depending on the MSC isolation protocol and cell culture conditions [4, 6] . Due to this, unmodified MSCs only interact with P-and E-selectin bearing substrates at low wall shear stresses <0.5 dyn/cm 2 , and the cell interaction is weak with rolling velocities that are w50% of the estimated free stream velocity [7, 8] . Thus, a low frequency of MSC capture results, with <2% of the infused cells being localized at the site of therapy [9, 10] . Because of the low capture frequency, the number of MSCs administered during systemic delivery is large with 0.4e10 million cells per kg bodyweight being introduced per infusion in human clinical trials [11, 12] . Such large infusions can diminish the benefits of MSC therapy since this can contribute to passive MSC entrapment either distal to the infusion site or in other organs like the lung and kidney [10,13e15] .
A variety of surface modification approaches have been undertaken in order to enhance the cell adhesion properties of MSCs since this can improve cell targeting. These methods employ viral transduction to over-express CXCR4 [16] , glycan engineering to enhance cellular sialyl Lewis-X (sLe x ) content [17] , covalent coupling to conjugate sLe x [18, 19] or E-selectin binding peptides [20] on the cell surface, or non-covalent lipid based methods to couple antibodies against vascular adhesion molecules ICAM-1, VCAM-1 and MAdCAM-1 [21, 22] . In addition to ex vivo testing, some of these studies report success in enhancing MSC homing in vivo following systemic infusion [16, 17, 22, 23] . Despite these outcomes, strategies to further enhance the efficiency of MSC capture from flowing blood are necessary in order to reduce the number of MSCs applied during therapeutic interventions.
Whereas the previous studies demonstrate that modified MSCs bound under static or low shear stress conditions can continue to adhere upon increasing wall shear stress, they do not demonstrate the direct efficient 'capture' or 'tethering' of MSCs from flow. This is because the molecular binding constants (on-rate, off-rate and K D ) for endothelial cell adhesion molecule binding to peptides, antibodies or portions of the natural selectin-ligand (i.e. sLe x alone) are not suitable for direct cell capture under flow conditions [24] . We overcome this limitation, here, by developing a non-covalent and non-viral strategy to functionalize MSCs with a pan-selectin ligand expressed natively on functional PSGL-1. This ligand, called 19Fc
, consists of the first 19 amino acids of PSGL-1 fused to a human IgG tail [25, 26] . A core-2 sialyl Lewis-X glycan is engineered at the N-terminus of this fusion protein in order to confer 'leukocyte-like' cell tethering and rolling properties to MSCs on substrates bearing P-and E-selectin under fluid shear conditions [27] . When immobilized onto MSCs using the palmitated protein G chemistry described earlier [28] , this strategy enables MSCs to tether and roll on endothelial cells similar to leukocytes.
Materials and methods

Antibodies
Mouse anti-human IgG monoclonal antibodies (mAbs) used in this study include anti-PSGL-1/CD162 clone KPL1 (BD Pharmingen, San Jose, CA), anti-P-selectin/ CD62P clone G1 (Ancell, Bayport, MN) and anti-E-selectin/CD62E clone CL2/6 (AbD Serotec, Raleigh, NC). Secondary Abs were from either Jackson ImmunoResearch (West Grove, PA) or Invitrogen (Grand Island, NY).
Cell culture
HEK293T cells (HEK, ATCC, Manassas, VA) and P-selectin bearing CHO-P cells available from a previous study were cultured in DMEM (Dulbecco's modified Eagle's medium) supplemented with 10% FBS [29] . Porcine MSCs were cultured in DMEM/F-12 (Cellgro, Manassas, VA) supplemented with 10% FBS and antimycotic (Invitrogen, Grand Island, NY) [14] . These cells were immortalized by cyclindependent kinasee1 (CDK1) reprogramming (US patent #20130058903). Human umbilical vein endothelial cells (HUVEC, Lonza, Allendale, NJ) were cultured in supplemented EGM-2 media (Lonza).
Expression, purification and characterization of 19Fc
Stable HEK cells expressing the a(1,3)fucosyltransferase FUT7 fused to a red fluorescence protein variant (FUT7-DsRED) were generated. To this end, DsRED (after deleting the start codon) was PCR amplified from mRFP-Ubiquitin (Plasmid 11935, Addgene, Cambridge, MA) and this was ligated into the pCS-CG lentiviral vector in place of the green fluorescence protein (Plasmid 12154, Addgene). Human FUT7 available from a previous study [30] was then amplified and ligated upstream of DsRED to make pCS-CG-FUT7-DsRED. Lentiviral particles for FUT7-DsRED were prepared as previously described [30] HisTrap HP column (GE Healthcare, Piscataway, NJ). Following a wash using 20 mM sodium phosphate buffer containing 500 mM NaCl and 50 mM imidazole, the protein was eluted by raising imidazole to 200 mM in the same buffer. 5e10 mg of 19Fc was produced using this procedure. Purified protein heated to 95 C in the absence (non-reducing condition) or presence (reducing condition) of 0.7 M b-mercaptoethanol was resolved using 4e 20% gradient SDS-PAGE. In some cases, these gels were silver stained using a kit from Thermo-Pierce (Rockford, IL). In other cases, the protein was transferred onto a nitrocellulose membrane for western blot analysis using anti-PSGL-1 mAb KPL1 and goat anti-human IgG for detection.
Matrix-assisted laser desorption/ionization-mass spectrometry (MALDI-MS)
19Fc and 19Fc[FUT7 þ ] were treated as described previously [31] . Briefly all samples were subjected to reduction in 4 M guanidine HCl (Thermo-Pierce) containing 2 mg/ml dithiothreitol, carboxymethylation, and trypsin digestion, and the digested glycoproteins were purified by C 18 -Sep-Pak (Waters Corp., Hertfordshire, UK). N-linked glycans were released by peptide:N-glycosidase F (EC 3.5.1.52, Roche Applied Science) digestion, whereas O-linked glycans were released by reductive elimination. N-and O-glycans were then permethylated using the sodium hydroxide procedure, and finally, the permethylated N-and O-glycans were purified by C 18 -Sep-Pak.
All permethylated samples were dissolved in 10 ml of methanol, and 1 ml of dissolved sample was premixed with 1 ml of matrix (for MS, 20 mg/ml 2,5-dihydroxybenzoic acid in 70% (v/v) aqueous methanol; for MS/MS, 20 mg/ml 3,4-diaminobenzophenone in 75% (v/v) aqueous acetonitrile). The mixture was then spotted onto a target plate (2 Â 0.5 ml), and dried under vacuum. MS data were acquired using a Voyager-DE STR MALDI-TOF (Applied Biosystems, Darmstadt, Germany). MS/MS data were acquired using a 4800 MALDI-TOF/TOF (Applied Biosystems) mass spectrometer. The collision energy was set to 1 kV, and argon was used as the collision gas. The 4700 calibration standard kit, Calmix (Applied Biosystems), was used as the external calibrant for the MS mode of both instruments, and [Glu1] fibrinopeptide B human (Sigma, St. Louis, MO) was used as an external calibrant for the MS/MS mode of the MALDI-TOF/TOF instrument.
The MS and MS/MS data were processed using Data Explorer 4.9 Software (Applied Biosystems). The spectra were subjected to manual assignment and annotation with the aid of the glycobioinformatics tool, GlycoWorkBench [32] . The proposed assignments for the selected peaks were based on 12 C isotopic composition together with knowledge of the biosynthetic pathways. The proposed structures were then confirmed by data obtained from MS/MS experiments.
Immobilization of 19Fc and 19Fc[FUT7 þ ] on HEK and MSC surface
Recombinant protein G and palmitic acid N-hydroxysuccinimide ester (NHSpalmitate) (both from Sigma) were coupled [28] . To this end, 0.1 mg/ml NHSpalmitate and 1 mg/ml protein G were incubated at 37 C for 20 h in PBS (pH 7.8) with 0.3% sodium deoxycholate, 0.1% sodium bicarbonate, and 0.1% sodium azide. The resulting palmitated-protein G conjugate or PPG, was then purified using a PD-10 desalting column (GE Healthcare, Piscataway, NJ) using PBS (pH 7.8) with 0.1% sodium deoxycholate as the elution buffer. The product was passed through a 0.45 mm cut-off membrane filter. Protein concentration was determined using a Coomassie Protein Assay Kit (Thermo-Pierce). The buffer was exchanged to PBS just prior to use.
HEK or MSC cells were trypsinized, washed twice and resuspended at 10 7 /mL with HEPES buffer (30 mM HEPES, 110 mM NaCl, 10 mM glucose, 10 mM KCl, 1 mM MgCl 2 , pH ¼ 7.2). PPG was added to cells at 50e100 mg/ml and the mixture was incubated at 37 C for 1 h with mild agitation. Cells were then washed twice with HEPES buffer prior to addition of 50e100 mg/ml purified 19Fc/19Fc[FUT7 þ ] or Alexa 488 conjugated goat anti-mouse Ab for 30 min at RT. The cells were then washed again in HEPES buffer prior to further experimentation.
Flow cytometry
2 Â 10 6 /mL cells in HEPES buffer were incubated with 5e10 mg/ml Ab at RT for 20 min. Samples were washed prior to analysis using a FACSCalibur flow cytometer (BD Biosciences).
Alkaline phosphatase assay
Cell viability was determined as necessary using a hemocytometer and the trypan blue exclusion test. The alkaline phosphate assay was either performed at day 0 using 4 Â 10 5 cells, or on days 1, 4 and 7 using cells removed from 6 well plates initially seeded with 2.5 Â 10 5 , 2 Â 10 5 and 1.5 Â 10 5 cells, respectively. For the latter time points, cells were removed with 0.25% trypsin/EDTA, and washed twice with HEPES buffer. 0.1% Triton-X in PBS was added to the cell pellet and the samples were crushed with a tissue grinder before centrifuging at 14,000 Â g for 20 min. The supernatant was removed and samples were normalized to equal protein concentrations. 20 ml of the normalized sample was added to 100 ml ALP (alkaline phosphatase) assay solution containing p-nitrophenol phosphate (Biomedical Research Service Center, Buffalo, NY) for 60 min at 37 C. Absorbance at 414 nm was measured using a Synergy 4 plate reader (BioTek, Winooski, VT).
Confocal microscopy
Cells were removed from culture dishes with trypsin before incubation with PPG and 19Fc[FUT7 þ ] described above. Next, the cells were washed and incubated with
for 20 min at RT, washed twice using HEPES buffer, fixed using HEPES containing 0.5% paraformaldehyde, pelleted, resuspended with ProLong Gold (Invitrogen) and mounted on microscope slides. Samples were imaged using a Zeiss LSM 710 AxioObserver confocal microscope (Jena, Germany) with a Plan-Apochromat 63x/1.40 Oil DIC objective. All images were acquired under identical exposure conditions.
19Fc/19Fc[FUT7 þ ] binding to platelets under shear
Blood was drawn from healthy human volunteers into 1:9 sodium citrate following human subject protocols approved by the University at Buffalo Institutional Review Board. Platelet rich plasma (PRP) was obtained by centrifugation of blood at 150 g for 12 min. Platelets in PRP were labeled using 0.5 nM BCECF (2 0 -7 0 -bis(carboxyethyl)-5(6)-carboxyfluorescein, Invitrogen). HEK/MSCs were stained with 2.7 mg/ml nuclear stain LDS-751 (Invitrogen) at 37 C. Following platelet activation using 18.8 mM TRAP-6 (thrombin receptor agonist peptide) for 5 min, 10 7 activated platelets/mL in HEPES buffer containing 1.5 mM CaCl 2 and 0.1% human serum albumin (abbreviated HEPES-Ca 2þ ) were mixed with 2 Â 10 6 /mL HEK/MSCs using a VT550 cone-plate viscometer (Thermo-Haake, Newington, NH) [33] . The applied shear rate was 650/s. 10 ml of sample collected at indicated times was diluted into 150 ml HEPES-Ca 2þ buffer and read immediately using the FACSCalibur flow cytometer. In some runs, platelet-cell adhesion was blocked by incubation of HEK/ MSCs with 10 mg/ml anti-PSGL-1 mAb KPL1 for 10 min. Unless otherwise indicated, all steps were conducted at room temperature.
Cell adhesion to selectin-bearing substrates
CHO-P and HUVECs were plated for 1e2 days on 100 mm 2 tissue culture dishes, and allowed to grow to confluence. HUVEC cells were stimulated for 4 h with 17 U/ ml human IL-1b (R&D Systems, Minneapolis, MN). The plates are washed once with PBS, a custom 1 cm long Â 400 mm wide Â 100 mm tall parallel-plate microfluidic flow chamber made of polydimethylsiloxane (PDMS) was vacuum sealed on the selectin-bearing cells, and then the entire assembly was mounted on the stage of a Zeiss AxioObserver microscope (Thornwood, NY). 2-5 Â 10 6 HEK or MSCs/mL suspended in HEPES-Ca 2þ buffer were then perfused over the selectin-bearing substrate at various wall shear stresses. Cell interactions were recorded using a Hamamatsu 1394 ORCA camera (Bridgewater, NJ). Analysis was performed by manually counting the cells at 2:30 min after the start of flow using NIH-ImageJ software. Interacting cells were defined as the sum of the total number of rolling and adherent cells. Rolling velocity was calculated between 2:30 and 3:00 min by following the trajectory of individual cells. To confirm binding specificity, in some runs, 10 mg/ml anti-CD62P or anti-CD62E blocking mAbs were injected into the flow chamber for 10 min prior to the run. In other runs, 10 mg/ml anti-PSGL-1 mAb KPL1
was incubated with HEK/MSC cells for 10 min prior to cell perfusion into the flow chamber.
For studies that quantified cell retention over a range of wall shear stresses, MSCs bearing 19Fc[FUT7 þ ] were initially allowed to bind to stimulated HUVEC monolayers for 10 min under static conditions. The wall shear stress was then progressively step increased to 0.5, 1.5, 3, 5 and 10 dyn/cm 2 in 3 min intervals. In each interval, the density of interacting cells was measured 2:30 min after the initiation of that particular wall shear stress.
Statistics
Student's t-test was performed for dual comparisons. One-way ANOVA followed by the TukeyeKramer test was used for multiple comparisons. P-values <0.05 were considered significant. ] were dimeric with a molecular mass of w68 KDa. The proteins were obtained at >95% purity as determined using silver staining of SDS-PAGE gels (Fig. 1B) . Their identity was confirmed by performing western blot analysis, using anti-PSGL-1 and anti-human IgG antibodies for detection (Fig. 1B) .
Results
Expression of core-2 sialyl Lewis
N-glycans released using PNGaseF and O-glycans released by reductive b-elimination were permethylated and analyzed using ultra-high sensitivity MALDI-TOF mass spectrometry (Fig. 1CeF) . Additional MS/MS analysis was performed as necessary to aid peak assignment. As seen, the relative abundance of O-glycans on 19Fc was different from that on 19Fc[ 
HEK-PPG-19Fc[FUT7 þ ] binding to selectins under hydrodynamic shear
Studies were performed to determine if the non-covalent coupling strategy outlined in the preceding section is sufficient to support selectin mediated cell adhesion under hydrodynamic shear conditions. Such studies were performed using both a cone and plate viscometer and a microfluidics based parallel-plate flow chamber (Fig. 3) . In the viscometer studies (Fig. 3A) , HEK cells bearing either 19Fc or 19Fc[FUT7 þ ] were shear mixed with TRAP-6 activated human platelets which express P-selectin on their cell surface. The percentage of HEK cells that bound activated platelets was quantified using flow cytometry. As seen, 40e60% of the HEK cells bearing 19Fc [FUT7 þ ] bound to at least one platelet within 1e3 min of shear application. The binding was specific since it could be blocked by a function blocking anti-PSGL-1 mAb KPL1. HEK cells bearing 19Fc, which lacks the core-2 sLe x , did not bind platelet P-selectin. Wildtype HEK and HEK-PPG cells also did not bind activated platelets. Further, control studies verified that the anti-PSGL-1 mAb used in this study did not inhibit cell adhesion by trivially displacing 19Fc [FUT7 þ ] from the HEK cell surface (Supplemental Fig. S3 ).
The flow chamber experiments utilized a microfluidic flow cell. Here, various HEK cell types were perfused over substrates composed of either P-selectin bearing CHO-P cells (Fig. 3B ) or E-selectin bearing IL-1b stimulated HUVECs (Fig. 3C) ] was bound to the MSCs, its cell surface concentration decreased gradually to 66% of the original amount at 24 h, and 25% at 72 h (Fig. 4B) 5A ) and E-( backbone, binds all three members of the selectin family (L-, E-and P-selectin) under physiologic fluid shear conditions [34] . . In one approach, antibodies against immunoglobulin superfamily receptors (anti-ICAM-1, anti-VCAM-1, and anti-MAdCAM) were coupled onto MSCs in order to enhance their cell adhesion properties [21, 22] . This method required the stoppage of flow to allow MSC binding since the binding constants for protein-antibody binding are not optimum for cell capture under continuous flow. In agreement with this, the current study demonstrates that the coupling of anti-Pand E-selectin antibodies to MSCs alone does not enable cell tethering/capture from flow. A second strategy, utilizes viral transduction to express either an erbB2 artificial receptor [40] or CXCR4 [16] on MSCs in order to enhance cell homing properties. Such permanent viral modification strategies may raise safety concerns that are mitigated by the non-covalent coupling approach presented in the current manuscript. A third approach decorates the MSC surface with either sLe x [18] or E-selectin binding peptides that has been identified using phage display [20] . While sLe x modified cells rolled on recombinant P-selectin in vitro up to 0.75 dyn/cm 2 [18] , the in vivo rolling velocity of these cells in postcapillary venules was high at w60% of the velocity of noninteracting cells [19] . Here, functionalization of sLe x alone may be insufficient to enable stable rolling since, in natural selectinligands, this tetrasaccharide is presented in the context of a glycan-core and protein/lipid backbone structure [41] . The peptide conjugation approach also similarly demonstrates tethering onto E-selectin substrates at wall shear stress below 0.25 dyn/cm 2 [20] , though cell rolling was sustained at shear stresses up to 10 dyn/cm 2 after cell capture. One possible explanation for this is that the Eselectin binding peptide conjugate used in this study was originally designed using phage display for the purpose of competitively inhibiting E-selectin binding function and not specifically for capturing cells under shear flow. ] would enable cell tethering to P-and E-selectin, with HCELL enhancing the robustness of E-selectin mediated cell rolling. Such modification with HCELL may also enhance MSC diapedesis/transmigration as discussed below.
Transmigration across the endothelial barrier
In the multistep leukocyte cell adhesion cascade, leukocyte adhesion to the inflamed endothelium is followed by transmigration through the vessel wall. Though the current study does not focus on the mechanism of MSC extravasation from blood and the effect of 19Fc[FUT7 þ ] coupling on this process, others have studied the MSC transmigration step [5, 7, 42] . This diapedesis process has leukocyte-like features, only it occurs in the time scale of 30e120 min, compared to granulocytes which transmigrate within 2e6 min [42] . The initiation of MSC transmigration is preceded by the formation of non-apoptotic membrane blebs which push on and breach the endothelium, much like embryonic and tumor cells [42] . The complete transmigration mechanism has yet to be revealed, though several potential molecular players have been identified: VCAM-1/VLA-4, MMP-2, cytokines and chemokines (CXCL9, CXCL16, CCL20, and CCL25) [5, 43] . In these models, chemokine binding to G-protein-coupled receptors initiates MSC signaling through Gai thus promoting transmigration. As the MSCs begin to extravasate, protrusions form from the endothelial cells creating transmigratory cups that surround the MSC [42] . Both paracellular (via endothelial cell junctions) and transcellular (directly through endothelial cells) routes are thought to contribute to MSC transmigration [42] . Besides these canonical pathways that are beginning to be documented in native MSCs, the ex vivo a(1,3)-fucosylation of MSCs is also thought to trigger additional transmigration mechanisms via E-selectin dependent cell signaling. In A,B. 2e5 Â 10 6 MSCs/mL immobilized with either 100 mg/ml 19Fc[FUT7 þ ], 100e200 mg/ml anti-P-selectin mAb G1 or 100e200 mg/ml anti-E-selectin mAb CL2/6 were perfused over either P-selectin bearing CHO-P cells at a wall shear stress of 1 dyn/cm 2 
Conclusions
In summary, the ability to home MSCs for tissue repair under continuous flow is important in the context of systemic delivery. The current study demonstrates a simple and robust strategy to achieve this by coupling 19Fc [FUT7 þ ] to the MSC surface. Such functionalization enables leukocyte-like selectin mediated MSC tethering and rolling on stimulated endothelial cells under shear flow. 
